EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Three-year outcomes of maintenance nortriptyline treatment in late-life depression: a study of two fixed plasma levels



Three-year outcomes of maintenance nortriptyline treatment in late-life depression: a study of two fixed plasma levels



American Journal of Psychiatry 156(8): 1177-1181



Objective: This study compared the long-term efficacy of two fixed plasma levels of nortriptyline in preventing or delaying recurrence of major depression in elderly patients and in minimizing residual depressive symptoms and somatic complaints. Method: The authors randomly assigned 41 elderly patients with histories of recurrent major depression to 3-year, double-blind maintenance pharmacotherapy using nortriptyline, with controlled plasma concentrations of 80-120 ng/ml versus 40-60 ng/ml. The authors compared times to, and rates of, recurrence of major depression. They also compared frequencies of side effects, noncompliance episodes, and subsyndromal symptomatic flare-ups. Results: Major depressive episodes recurred for six (29%) of 21 subjects in the 80-120-ng/ml condition and eight (40%) of 20 subjects in the 40-60-ng/ml condition, a nonsignificant difference. Most recurrences took place in the first year of maintenance treatment. Hamilton depression scores in the subsyndromal range (higher than either 10 or 7) occurred significantly more often at 40-60 ng/ml, while constipation occurred significantly more often at 80-120 ng/ml. The proportions of patients reporting missed doses did not differ. Conclusions: Maintenance pharmacotherapy with nortriptyline at 80-120 ng/ml is associated with fewer residual depressive symptoms, that is, a less variable long-term response, than pharmacotherapy at 40-60 ng/ml, but constipation is more frequent and there is no difference in recurrence of syndromal major depressive episodes. Treatment at 80-120 ng/ml may be preferable, because of fewer residual symptoms and less variability of response, as long as side effect burden can be managed successfully.

(PDF emailed within 0-6 h: $19.90)

Accession: 011567539

Download citation: RISBibTeXText

PMID: 10450257

DOI: 10.1176/ajp.156.8.1177



Related references

Continuation/maintenance treatment with nortriptyline versus combined nortriptyline and ECT in late-life psychotic depression: a two-year randomized study. American Journal of Geriatric Psychiatry 16(6): 498-505, 2008

Maintenance treatment for recurrent depression in late life. A four-year outcome study. American Journal of Geriatric Psychiatry 8(2): 112-116, 2000

A double-blind randomized comparison of nortriptyline plus perphenazine versus nortriptyline plus placebo in the treatment of psychotic depression in late life. Journal of Clinical Psychiatry 62(8): 597-604, 2001

Impact of cluster C personality disorders on outcomes of acute and maintenance treatment in late-life depression. American Journal of Geriatric Psychiatry 13(9): 808-814, 2005

High plasma nortriptyline levels in the treatment of depression. I. Clinical Pharmacology and Therapeutics 23(3): 309-314, 1978

Plasma levels of nortriptyline in the treatment of endogenous depression. Acta Psychiatrica Scandinavica 49(4): 444-456, 1973

Long-term treatment of endogenous depression with nortriptyline with control of plasma levels. Psychological Medicine 4(2): 174-180, 1974

Relationships among nortriptyline, 10-OH(E)nortriptyline, and 10-OH(Z)nortriptyline steady-state plasma levels and nortriptyline dosage. Therapeutic Drug Monitoring 11(3): 221-227, 1989

A double-blind randomized comparison of nortriptyline and paroxetine in the treatment of late-life depression: 6-week outcome. Journal of Clinical Psychiatry 60 Suppl 20: 16-20, 1999

Citalopram versus nortriptyline in late-life depression: A 12-week randomized single-blind study. Acta Psychiatrica Scandinavica 103(6): 435-440, June, 2001

A double-blind, placebo-controlled assessment of nortriptyline's side-effects during 3-year maintenance treatment in elderly patients with recurrent major depression. International Journal of Geriatric Psychiatry 14(12): 1014-1018, 1999

Changes in pro-inflammatory cytokine levels and late-life depression: A two year population based longitudinal study. Psychoneuroendocrinology 90: 85-91, 2018

Changes in pro-inflammatory cytokine levels and late-life depression: A two year population based longitudinal study. Psychoneuroendocrinology 90: 85-91, 2018

Quality of life and psychosocial outcomes after fixed orthodontic treatment: a 17-year observational cohort study. Community Dentistry and Oral Epidemiology 39(6): 505-514, 2012

Which elderly depressed patients remain well on maintenance interpersonal psychotherapy alone?: report from the Pittsburgh study of maintenance therapies in late-life depression. Depression and Anxiety 10(2): 55-60, 1999